Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 1:02 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 6,060 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Matched control Clear all
Completed Not applicable Interventional Accepts healthy volunteers

The Effects of Exercise on Emotion Regulation and Cognitive Control in PTSD

NCT05643716
View directory record Official record
Conditions
Emotion Regulation, Cognitive Control, PTSD
Interventions
Aerobic Exercise
Behavioral
Lead sponsor
Michigan State University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
East Lansing, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 18, 2025 · Synced Oct 20, 2026, 1:02 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Cardiac Effects of Danicopan in Healthy Adults

NCT05016206
View directory record Official record
Conditions
Healthy
Interventions
Danicopan, Moxifloxacin-matching Placebo, Danicopan-matching placebo, Moxifloxacin
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 23, 2021 · Synced Oct 20, 2026, 1:02 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Study of BMF-650 in Otherwise Healthy Overweight or Obese Adult Participants

NCT07223216
View directory record Official record
Conditions
Obesity
Interventions
BMF-650
Drug
Lead sponsor
Biomea Fusion Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Oct 20, 2026, 1:02 PM EDT
Completed Not applicable Interventional Results available

A Study to Evaluate a Single Intravenous Dose of Motavizumab for the Treatment of Children Hospitalized With Respiratory Syncytial Virus (RSV) Illness

NCT00421304
View directory record Official record
Conditions
RSV Illness in ≤12 Months of Participants
Interventions
Motavizumab, Placebo
Biological · Other
Lead sponsor
MedImmune LLC
Industry
Eligibility
0 Months to 12 Months
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
26
States / cities
Tucson, Arizona • Long Beach, California • Orange, California + 23 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2021 · Synced Oct 20, 2026, 1:02 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of PLX5622 in Healthy Adult Volunteers

NCT01282684
View directory record Official record
Conditions
Healthy
Interventions
PLX5622, Placebo
Drug
Lead sponsor
Plexxikon
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Mar 30, 2015 · Synced Oct 20, 2026, 1:02 PM EDT
Completed Phase 2 Interventional Results available

Effect of KNO3 Compared to KCl on Oxygen UpTake in Heart Failure With Preserved Ejection Fraction (KNO3CK OUT HFPEF)

NCT02840799
View directory record Official record
Conditions
Heart Failure
Interventions
Potassium Nitrate (KNO3), Potassium Chloride (KCl)
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 90 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
3
States / cities
Evanston, Illinois • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 18, 2023 · Synced Oct 20, 2026, 1:02 PM EDT
Terminated Not applicable Interventional Results available

Feasibility and Acceptability of Stress Induction, Physiological Data Collection, and Mindfulness-Based Stress Reduction Among Combat Veterans With PTSD

NCT05938816
View directory record Official record
Conditions
Ptsd
Interventions
Mindfulness-Based Stress Reduction (MBSR), Health and Wellness Education (HWE)
Behavioral
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 85 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Nov 5, 2024 · Synced Oct 20, 2026, 1:02 PM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Role of Pregnancy Related Hormones in Lowering the Insulin Requirement in Pregnant Women With Type 1 Diabetes

NCT01265017
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Estradiol, medroxyprogesterone, hydrocortisone, GH, Matching placebo
Drug
Lead sponsor
Sansum Diabetes Research Institute
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2020
U.S. locations
1
States / cities
Santa Barbara, California
Source: ClinicalTrials.gov public record
Updated Apr 18, 2018 · Synced Oct 20, 2026, 1:02 PM EDT
Completed Phase 2 Interventional Results available

Solifenacin Succinate With Tamsulosin HCl in Males With Lower Urinary Tract Symptoms and Bladder Outlet Obstruction

NCT00507455
View directory record Official record
Conditions
Lower Urinary Tract Symptoms, Bladder Outlet Obstruction
Interventions
solifenacin succinate, tamsulosin hydrochloride, Placebo to solifenacin, Placebo to tamsulosin
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
45 Years and older · Male only
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
17
States / cities
Homewood, Alabama • La Mesa, California • Long Beach, California + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2014 · Synced Oct 20, 2026, 1:02 PM EDT
Completed Phase 2 Interventional Results available

AGN-151586 Dose-Ranging Study for Treatment of Glabellar Lines

NCT04096326
View directory record Official record
Conditions
Glabellar Lines
Interventions
AGN-151586, Placebo
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 65 Years
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
9
States / cities
Fremont, California • Santa Monica, California • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2023 · Synced Oct 20, 2026, 1:02 PM EDT
Completed Phase 2 Interventional Results available

Xyrem(Sodium Oxybate) and Ambien(Zolpidem Tartrate) in the Treatment of Chronic Insomnia.

NCT00383643
View directory record Official record
Conditions
Sleep Initiation and Maintenance Disorders
Interventions
zolpidem tartrate, sodium oxybate, Matching Placebos
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 75 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 1, 2017 · Synced Oct 20, 2026, 1:02 PM EDT
Completed Phase 4 Interventional Results available

A Study Evaluating TEPEZZA® Treatment in Patients With Chronic (Inactive) Thyroid Eye Disease

NCT04583735
View directory record Official record
Conditions
Thyroid Eye Disease, Chronic (Inactive) Thyroid Eye Disease
Interventions
TEPEZZA, Placebo
Biological · Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
12
States / cities
Beverly Hills, California • La Jolla, California • Los Angeles, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2024 · Synced Oct 20, 2026, 1:02 PM EDT
Terminated Phase 2 Interventional Results available

Vitamin D and n-3 Polyunsaturated Fatty Acids (PUFAs) to Prevent Chronic Pain Following Major Thermal Burn Injury

NCT03313076
View directory record Official record
Conditions
Chronic Pain Following Thermal Burn Injury
Interventions
Omega-3 fatty acids (fish oil), Vitamin D3 (cholecalciferol), Vitamin D3 (cholecalciferol) placebo, Omega-3 fatty acid placebo
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 20, 2026, 1:02 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Two-Part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2006 in Healthy Japanese and White Subjects

NCT02039089
View directory record Official record
Conditions
Healthy Volunteers
Interventions
E2006 2.5 mg, E2006 10 mg, E2006 25 mg, Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
20 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Nov 3, 2015 · Synced Oct 20, 2026, 1:02 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Brain Training in Preterm Children at Risk for Inattention, Hyperactivity, and Executive Function Impairment

NCT02588391
View directory record Official record
Conditions
Premature Birth
Interventions
Brain Training (Active), Brain Training (Passive), Brain Training (Active or Passive)
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
4 Years to 5 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 6, 2019 · Synced Oct 20, 2026, 1:02 PM EDT
Completed Phase 3 Interventional Results available

Trial of Linaclotide Administered to Patients With Irritable Bowel Syndrome With Constipation

NCT00948818
View directory record Official record
Conditions
Irritable Bowel Syndrome Characterized by Constipation
Interventions
Linaclotide 290 micrograms, Matching placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
803 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
111
States / cities
Birmingham, Alabama • Hueytown, Alabama • Huntsville, Alabama + 94 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2013 · Synced Oct 20, 2026, 1:02 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Multiple Dose Study of LY3023703 in Healthy Participants

NCT01849055
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Placebo, LY3023703, Celecoxib
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 60 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 14, 2018 · Synced Oct 20, 2026, 1:02 PM EDT
Completed Phase 2 Interventional Results available

A Multi-Center Study of Riociguat in Patients With Sickle Cell Diseases

NCT02633397
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Riociguat, Placebo
Drug
Lead sponsor
Mark Gladwin
Other
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
20
States / cities
Oakland, California • Washington D.C., District of Columbia • Miami, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2023 · Synced Oct 20, 2026, 1:02 PM EDT
Active, not recruiting Not applicable Interventional

TMS-EEG Biomarkers for Chronic Pain

NCT07116278
View directory record Official record
Conditions
Chronic Pain
Interventions
QuantalX DELPHI-MD (TMS-EEG)
Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 20, 2026, 1:02 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Tolerance and Safety of a Ketone-Promoting Food Ingredient

NCT04707989
View directory record Official record
Conditions
Tolerance
Interventions
Ketone- Promoting Food Ingredient #1, Ketone- Promoting Food Ingredient #2, Ketone Free Placebo
Other
Lead sponsor
BHB Therapeutics, Ireland LTD
Industry
Eligibility
18 Years to 65 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Addison, Illinois
Source: ClinicalTrials.gov public record
Updated May 10, 2021 · Synced Oct 20, 2026, 1:02 PM EDT
Terminated Phase 2 Interventional

Efficacy and Safety Study of Etodolac and Propranolol in Patients With Clinically Progressive Prostate Cancer

NCT01857817
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
VT-122, Placebo
Drug
Lead sponsor
Vicus Therapeutics
Industry
Eligibility
18 Years and older · Male only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
16
States / cities
Fayetteville, Arkansas • Santa Rosa, California • Parker, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2018 · Synced Oct 20, 2026, 1:02 PM EDT
Completed Phase 3 Interventional Results available

A Study of Roxadustat for the Treatment of Anemia in Participants With Chronic Kidney Disease and Not Receiving Dialysis

NCT01750190
View directory record Official record
Conditions
CKD Anemia
Interventions
Roxadustat, Placebo
Drug
Lead sponsor
Kyntra Bio
Industry
Eligibility
18 Years and older
Enrollment
922 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
55
States / cities
Huntsville, Alabama • Tempe, Arizona • Alhambra, California + 48 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2021 · Synced Oct 20, 2026, 1:02 PM EDT
Terminated Phase 3 Interventional

Batiraxcept (AVB-S6-500)/Placebo in Combination With Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian Cancer

NCT04729608
View directory record Official record
Conditions
Platinum-resistant Ovarian Cancer
Interventions
Batiraxcept, Paclitaxel, Placebo
Drug · Other
Lead sponsor
Aravive, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
366 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
84
States / cities
Mobile, Alabama • Burbank, California • Los Angeles, California + 74 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2023 · Synced Oct 20, 2026, 1:02 PM EDT
Active, not recruiting Phase 3 Interventional

Evaluation of Maralixibat in Pruritus Associated With General Cholestatic Liver Disease (EXPAND)

NCT06553768
View directory record Official record
Conditions
Cholestatic Liver Disease (Except ALGS, PFIC, PBC and PSC)
Interventions
Maralixibat, Placebo
Drug · Other
Lead sponsor
Mirum Pharmaceuticals, Inc.
Industry
Eligibility
6 Months and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
8
States / cities
Los Angeles, California • Palo Alto, California • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 20, 2026, 1:02 PM EDT